The magnitude of best tumor shrinkage during second-line targeted therapy affects progression-free survival but not overall survival in patients with metastatic renal cell carcinoma-Reference-Cited by-同舟云学术

The magnitude of best tumor shrinkage during second-line targeted therapy affects progression-free survival but not overall survival in patients with metastatic renal cell carcinoma

Published:2016-06-01 Issue:6 Volume:46 Page:568-574
ISSN:1465-3621
Container-title:Japanese Journal of Clinical Oncology
language:en
Short-container-title:

Author:

Ishihara Hiroki¹,Kondo Tsunenori¹,Omae Kenji¹,Takagi Toshio¹,Izuka Jumpei¹,Kobayashi Hirohito¹,Tanabe Kazunari¹

Affiliation:

1. Department of Urology, Kidney Center, Tokyo Women's Medical University, Shinjuku-ku, Tokyo, Japan

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://academic.oup.com/jjco/article-pdf/46/6/568/26649972/hyw024.pdf

Reference14 articles.

1. Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness;Thompson Coon;Br J Cancer,2009

2. Metastatic renal cell cancer treatments: an indirect comparison meta-analysis;Mills;BMC Cancer,2009

3. Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors;Busch;Eur Urol,2011

4. Retrospective comparison of triple-sequence therapies in metastatic renal cell carcinoma;Busch;Eur Urol,2013

5. Tumour shrinkage measured with first treatment evaluation under VEGF-targeted therapy as prognostic marker in metastatic renal cell carcinoma (mRCC);Seidel;Br J Cancer,2013

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of nivolumab versus molecular‐targeted therapy as second‐line therapy for metastatic renal cell carcinoma: Real‐world data from two Japanese institutions;International Journal of Urology;2020-11-06

2. Efficacy of immune checkpoint inhibitor monotherapy for patients with massive non-small-cell lung cancer;Journal of Cancer Research and Clinical Oncology;2020-05-27

3. Correlation between the magnitude of best tumor response and patient survival in nivolumab therapy for metastatic renal cell carcinoma;Medical Oncology;2019-03-16

4. Tumor shrinkage rate as a potential marker for the prediction of long-term outcome in advanced non-small cell lung cancer treated with first-line tyrosine kinase inhibitors;Journal of Cancer Research and Therapeutics;2019

5. Prognostic Impact of the Components of Progressive Disease on Survival After First-Line Tyrosine Kinase Inhibitor Therapy for Metastatic Renal Cell Carcinoma;Targeted Oncology;2018-05-21